Analysis of the relationship between cytokine expression and chronic obstructive pulmonary disease and lung cancer detected by liquid chip

doi:10.3877/cma.j.issn.1674-6902.2026.05.015

Abstract

Abstract:

Objective

To investigate the relationship between cytokine levels and the lesion degree, clinical significance and prognosis of patients with chronic obstructive pulmonary disease(COPD) complicated lung cancer by liquid chip technology.

Methods

A series of 130 patients with simple COPD(control group) and 57 patients with COPD combined with lung cancer( observation group)treated in our hospital from January 2020 to January 2025 were selected as study objects. According to the 2015 GOLD guidelines, patients in the combined group were divided into mild 53 cases, moderate 48 cases, severe 28 cases and extremely severe 16 cases. Serum interleukin (IL)-22, IL-17, IL-6, IL-8 and tumor necrosis factor (TNF)α were expressed by liquid chip technology. The relationship between the levels of IL-22, IL-17, IL-6, IL-8 and clinical features was analyzed. The median value of IL-22, IL-17, IL-6, IL-8 and TNF-α was used as the standard, higher than this value was the high expression group, otherwise the low expression group, and the prognostic difference was analyzed.

Results

In observation group IL-22(0.42±0.10)pg/ml, IL-17(8.28±1.32)pg/ml, IL-6(63.22±9.15)ng/L、IL-8(25.44±4.10)ng/L, TNF-α(0.86±0.12)pg/ml higher than control group(0.37±0.05)pg/ml, (5.90±0.60)pg/ml, (39.67±5.08)ng/L, (60.08±5.99)ng/L, (0.51±0.07)pg/ml(P<0.05). The levels of IL-22, IL-17, IL-6, IL-8 and TNF-α were correlated with TNM stage (P<0.05). The expression levels of IL-22 and IL-17 were correlated with lymph node metastasis and distant metastasis in patients (P<0.05). Compared with mild COPD patients with lung cancer, the levels of IL-22, IL-17, IL-6, IL-8 and TNF-α were increased (P<0.05). Compared with moderate patients, the level of IL-6 was higher in severe patients (P<0.05). The 2-year overall survival rate of patients with high expression of IL-17, IL-6, IL-8 and TNF-α was lower than that of patients with low expression (P<0.05).

Conclusion

The detection of IL-22, IL-17, IL-6, IL-8 and TNF-α by liquid chip technology in patients with COPD complicated with lung cancer can better reflect the severity of the patient′s disease, and the expression level of some cytokines is related to clinical stage and prognosis.

Key words: Chronic obstructive pulmonary disease, Bronchogenic carcinoma, Liquid chip, Cytokines, Prognosis

Renli Xu, Ming Tan, Min Fu, Shiqiang Li, Jie Zhang, Gaoling Zhu, Liang Chen. Analysis of the relationship between cytokine expression and chronic obstructive pulmonary disease and lung cancer detected by liquid chip[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2026, 19(05): 820-825.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2026.05.015

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2026/V19/I05/820

Figures/Tables 3

References 26

1	高瞻，唐莎莎，秦蘅，等. 慢性阻塞性肺疾病合并肺癌的临床特征及危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(5): 685-690.
2	Qi C, Sun SW, Xiong XZ. From COPD to lung cancer: mechanisms linking, diagnosis, treatment, and prognosis[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17(17): 2603-2621.
3	赵明，宋勇，戴伟，等. NLRP3炎症小体表达与慢性阻塞性肺疾病合并肺癌的相关性研究[J]. 现代生物医学进展，2019, 19(8): 1436-1440.
4	李玲，赵兵. 血清IL-6、IL-8水平与慢阻肺急性加重期患者临床预后的相关性[J]. 中国实用医刊，2023, 50(16): 48-51.
5	Wu LL, Lin GH. Analysis of the clinical diagnostic and prognostic value of SAA, IL-17, and Th17/Treg in elderly patients with chronic obstructive pulmonary disease complicated by lower respiratory tract infection[J]. Int Arch Allergy Immunol, 2025: 1-10.
6	白莹，马娟，吕欣，等. 慢性阻塞性肺疾病合并肺癌临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2021, 14(3): 265-271.
7	中华人民共和国国家卫生健康委员会. 原发性肺癌诊疗指南(2022年版)[J]. 中国合理用药探索，2022, 19(9): 1-28.
8	陈亚红. 2020年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J/OL]. 中国医学前沿杂志(电子版), 2019, 11(12): 32-50.
9	Hendriks LE, Kerr KM, Menis J, et al. ESMO guidelines committee. electronic address: clinicalguidelines@esmo.org. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(4): 358-376.
10	Hou W, Hu S, Li C，et al. Cigarette smoke induced lung barrier dysfunction, EMT, and tissue remodeling: A possible link between COPD and lung cancer[J]. Biomed Res Int, 2019, 2019: 2025636.
11	马银龙，张玉良，杜容宇，等. 血清miR-21、miR-155与炎症因子水平在肺癌患者围手术期感染中的变化及其临床意义[J]. 实用癌症杂志，2022, 37(4): 552-555.
12	Terlizzi M, Colarusso C, Somma P, et al. S1P-induced TNF-α and IL-6 release from PBMCs exacerbates lung cancer-associated inflammation[J]. Cells, 2022, 11(16): 2524.
13	韦鹏，吴丽娟，罗毅沣，等. 血清皮质醇及相关炎症因子在慢性阻塞性肺疾病急性加重期患者中表达特征的初步研究[J]. 右江医学，2022, 50(11): 807-812.
14	邓清洋，孙建，冯晓丽，等. COPD患者血清炎症指标与气道炎症的关系[J]. 西部医学，2020, 32(1): 69-72.
15	Fang Aili, Li Buwu, Chen Sheng. Effects of Inhaled corticosteroids/long-acting beta-agonists (ICS/LABA) on airway microbial diversity and IL-8/IL-10 cytokine levels in stable COPD[J]. Comb Chem High Throughput Screen, 2025. doi: 10.2174/0113862073349683241226100233.
16	Liao X, Zhang W, Dai H, et al. Neutrophil-derived IL-17 promotes ventilator-induced lung injury via p38 MAPK/MCP-1 pathway activation[J]. Front Immunol, 2021, 12: 768813.
17	Ferreira N, Mesquita I, Baltazar F, et al. IL-17A and IL-17F orchestrate macrophages to promote lung cancer[J]. Cell Oncol (Dordr), 2020, 43(4): 643-654.
18	李林，杨智晖，刘青，等. 血清IL-6, IL-8, TNF-α在COPD患者肺癌辅助诊断中的价值分析[J]. 川北医学院学报，2019, 34(3): 344-348.
19	Zeng Y, Zhang Q, Wang H, et al. Prognostic significance of interleukin-17 in solid tumors: a meta-analysis[J]. Int J Clin Exp Med, 2015, 8(7): 10515-10536.
20	崔东，许广辉，贾忠伟，等. NLR、VEGF、IL-6、TNF-α水平与非小细胞肺癌预后的相关性[J]. 现代肿瘤医学，2019, 27(14): 2514-2518.
21	杨忠信，李晓宇，陈涛，等. IL-8和MMP-2在非小细胞肺癌患者胸腔镜肺段切除术预后评估中的价值[J]. 检验医学，2023, 38(4): 342-346.
22	方恩容，何杰，黄娜，等. 沙美特罗替卡松粉吸入剂联合胸腺五肽治疗COPD患者的疗效及对血清IL-8、CTRP-4、CTRP-5的影响[J]. 西部医学，2019, 31(4): 561-565.
23	王鑫，支修益. 国际肺癌研究协会(IASLC)第八版肺癌TNM分期解读[J/OL]. 中华胸部外科电子杂志，2016, 3(2): 70-76.
24	陈亚红. 2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J/OL]. 中国医学前沿杂志(电子版), 2019, 11(1): 1-14.
25	MacRedmond RE, Greene CM, Dorscheid DR, et al. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke[J]. Respir Res, 2007, 8(1): 84.
26	王振桂，王喜泰，郑映芳. 胸腺五肽辅助治疗慢性阻塞性肺疾病患者的效果观察[J]. 慢性病学杂志，2021, 22(3): 466-468.

组　别	例数	IL-22(pg/ml)	IL-17(pg/ml)	IL-6(ng/l)	IL-8(ng/l)	TNF-α(pg/ml)
观察组	57	0.42±0.10	8.28±1.32	63.22±9.15	25.44±4.10	0.86±0.12
对照组	130	0.38±0.06	5.95±0.65	39.85±5.15	60.15±6.10	0.52±0.08
F值		485.600	1 850.000	1 520.000	2 350.000	1 050.000
P值		0.000	0.000	0.000	0.000	0.000

组　别	例数	IL-22(pg/ml)	IL-17(pg/ml)	IL-6(ng/l)	IL-8(ng/l)	TNF-α(pg/ml)
观察组	57	0.42±0.10	8.28±1.32	63.22±9.15	25.44±4.10	0.86±0.12
对照组	130	0.38±0.06	5.95±0.65	39.85±5.15	60.15±6.10	0.52±0.08
F值		485.600	1 850.000	1 520.000	2 350.000	1 050.000
P值		0.000	0.000	0.000	0.000	0.000

临床资料	例数	IL-22(pg/ml)	IL-17(pg/ml)	IL-6(ng/L)	IL-8(ng/L)	TNF-α(pg/ml)
年龄
<60岁	26	0.40±0.09	8.19±1.28	62.50±9.20	24.83±3.60	0.83±0.08
≥60岁	31	0.44±0.11	8.33±1.20	63.94±8.10	26.05±3.11	0.89±0.07
性别
男	33	0.41±0.08	8.20±1.30	63.16±9.11	25.06±4.01	0.88±0.08
女	24	0.43±0.12	8.37±1.33	63.28±8.86	25.82±3.66	0.84±0.09
是否吸烟
是	17	0.43±0.11	8.35±1.28	64.66±7.70	26.77±2.90	0.89±0.08
否	40	0.41±0.09	8.27±1.18	61.80±9.20	24.11±3.05	0.83±0.07
病理类型
鳞癌	27	0.44±0.12	8.30±1.40	62.77±8.20	25.24±3.10	0.85±0.08
腺癌	30	0.41±0.09	8.36±1.26	63.67±7.93	25.64±3.02	0.87±0.10
TNM分期
Ⅱ~Ⅲa期	32	0.41±0.10	8.05±1.14	60.15±5.90	23.30±2.02	0.80±0.06
Ⅲb~Ⅳ期	25	0.44±0.08^a	8.51±1.34^a	66.29±5.71	27.58±1.80^a	0.92±0.05^a
淋巴结转移
是	29	0.45±0.12	8.47±1.33	63.19±6.60	26.33±2.54	0.87±0.10
否	28	0.39±0.07^a	8.09±1.40^a	63.25±6.28	24.55±3.02	0.85±0.11
远处转移	12	0.48±0.07	8.85±0.91	64.04±5.00	27.15±1.51	0.89±0.07
未远处转移	17	0.43±0.05^a	8.20±1.10^a	62.58±5.11	25.73±2.16	0.86±0.10
骨转移	6	0.49±0.04	8.87±0.89	64.25±4.87	26.91±1.96	0.86±0.10
肝转移	3	0.48±0.06	8.88±0.91	63.89±5.10	27.50±1.50	0.94±0.02
脑转移	2	0.47±0.05	8.76±0.84	63.80±5.02	27.00±1.66	0.92±0.04
其他	1	0.47±0.07	8.85±0.87	63.49±5.39	27.84±1.08	0.86±0.08

临床资料	例数	IL-22(pg/ml)	IL-17(pg/ml)	IL-6(ng/L)	IL-8(ng/L)	TNF-α(pg/ml)
年龄
<60岁	26	0.40±0.09	8.19±1.28	62.50±9.20	24.83±3.60	0.83±0.08
≥60岁	31	0.44±0.11	8.33±1.20	63.94±8.10	26.05±3.11	0.89±0.07
性别
男	33	0.41±0.08	8.20±1.30	63.16±9.11	25.06±4.01	0.88±0.08
女	24	0.43±0.12	8.37±1.33	63.28±8.86	25.82±3.66	0.84±0.09
是否吸烟
是	17	0.43±0.11	8.35±1.28	64.66±7.70	26.77±2.90	0.89±0.08
否	40	0.41±0.09	8.27±1.18	61.80±9.20	24.11±3.05	0.83±0.07
病理类型
鳞癌	27	0.44±0.12	8.30±1.40	62.77±8.20	25.24±3.10	0.85±0.08
腺癌	30	0.41±0.09	8.36±1.26	63.67±7.93	25.64±3.02	0.87±0.10
TNM分期
Ⅱ~Ⅲa期	32	0.41±0.10	8.05±1.14	60.15±5.90	23.30±2.02	0.80±0.06
Ⅲb~Ⅳ期	25	0.44±0.08^a	8.51±1.34^a	66.29±5.71	27.58±1.80^a	0.92±0.05^a
淋巴结转移
是	29	0.45±0.12	8.47±1.33	63.19±6.60	26.33±2.54	0.87±0.10
否	28	0.39±0.07^a	8.09±1.40^a	63.25±6.28	24.55±3.02	0.85±0.11
远处转移	12	0.48±0.07	8.85±0.91	64.04±5.00	27.15±1.51	0.89±0.07
未远处转移	17	0.43±0.05^a	8.20±1.10^a	62.58±5.11	25.73±2.16	0.86±0.10
骨转移	6	0.49±0.04	8.87±0.89	64.25±4.87	26.91±1.96	0.86±0.10
肝转移	3	0.48±0.06	8.88±0.91	63.89±5.10	27.50±1.50	0.94±0.02
脑转移	2	0.47±0.05	8.76±0.84	63.80±5.02	27.00±1.66	0.92±0.04
其他	1	0.47±0.07	8.85±0.87	63.49±5.39	27.84±1.08	0.86±0.08

组　别	例数	IL-22(pg/ml)	IL-17(pg/ml)	IL-6(ng/L)	IL-8(ng/L)	TNF-α(pg/ml)
轻度	21	0.36±0.03	7.71±0.35	59.50±3.60	23.68±1.25	0.81±0.04
中度	19	0.41±0.07	8.35±0.86	63.20±4.15	25.60±4.11	0.86±0.07
重度	11	0.45±0.06	8.63±0.70	67.50±4.60^a	26.70±3.50	0.91±0.08
极重度	6	0.48±0.04^a	9.11±0.45^a	70.10±1.75^a	28.04±1.14^a	0.94±0.04^a
F值		11.630	10.060	17.190	4.601	22.400
P值		0.001	0.001	0.001	0.006	0.001

Please choose a citation manager

Content to export